Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study
Journal
Anticancer research
Journal Volume
42
Journal Issue
9
Pages
4461
Date Issued
2022-09
Author(s)
Abstract
The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread. This study explored sorafenib treatment outcomes before and after this expansion.
Subjects
Barcelona Clinic Liver Cancer Stage C; Hepatocellular carcinoma; National Health Insurance; reimbursement criteria; sorafenib; transarterial chemoembolization
SDGs
Publisher
INT INST ANTICANCER RESEARCH
Type
journal article